Aleks Radovic-Moreno

Dr. Radovic-Moreno is an Entrepreneur-in-Residence at Longwood Fund, where he is involved in building and supporting portfolio companies. He was previously Senior Vice President at PureTech Health (LSE: PRTC), where he was a co-founder and member of the senior leadership team of several portfolio companies.

Dr. Radovic-Moreno was a co-founder of Vor Biopharma, a company developing novel engineered hematopoietic stem cell therapies for treating blood cancers. At Vor, Dr. Radovic-Moreno led a fundraising effort that culminated in a $42M Series A financing led by 5AM Ventures & RA Capital in 2019. He also co-founded and acted as interim CEO of Alivio Therapeutics, a company focused on developing new therapies for autoimmune and inflammatory diseases based on a new category of inflammation-targeting drugs. He was previously a scientist at Exicure, where he was the lead inventor of AST-008, a TLR9 agonist now in phase 2 trials for treating various solid tumors.

Dr. Radovic-Moreno completed his graduate work as an NSF Fellow in Robert Langer's lab at MIT, where he developed novel strategies for managing bacterial infections, including a novel vaccine candidate for chlamydia infections. Dr. Radovic-Moreno was awarded the Alumni Achievement Award by the Pennsylvania State University for extraordinary professional accomplishment by graduates under the age of 35. Dr. Radovic-Moreno received his B.S. in Chemical Engineering from the Pennsylvania State University and PhD in Chemical and Biomedical Engineering from MIT and the Harvard-MIT Division of Health Sciences & Technology.